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OBJECTIVE — Weinvestigatedtheprevalenceofsarcopenicobesity(SO)anditsrelationship
with metabolic syndrome in a community-based elderly cohort in Korea.
RESEARCHDESIGNANDMETHODS — Inthisstudy,287menand278womenaged
65 or older were recruited. Sarcopenia was deﬁned as the appendicular skeletal muscle mass
(ASM) divided by height squared (Ht
2) (kg/m
2) or by weight (Wt) (%) of 1 SD below the
sex-speciﬁc mean for young adults. Obesity was deﬁned as a visceral fat area 100 cm
2.
RESULTS — The prevalence of SO was 16.7% in men and 5.7% in women with sarcopenia
deﬁned by ASM/Ht
2; however, it was 35.1% in men and 48.1% in women by ASM/Wt. Using
ASM/Wt,thehomeostasismodelassessmentofinsulinresistanceofsubjectswithSOwashigher
andtheywereathigherriskformetabolicsyndrome(oddsratio[OR]8.28[95%CI4.45–15.40])
than the obese (5.51 [2.81–10.80]) or sarcopenic group (2.64 [1.08–6.44]).
CONCLUSIONS — SO deﬁned by ASM/Wt was more closely associated with metabolic
syndrome than either sarcopenia or obesity alone.
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T
henumberofobeseelderlypeopleis
increasingworldwide.Agingisasso-
ciated with increased fat mass and
reduced muscle mass or strength, even in
those with stable body weight. This sar-
copenic obesity (SO) is associated with
deteriorations in physical disability, mor-
bidity, and mortality. Therefore, sarcope-
nia and obesity might act synergistically
on metabolic and functional impairments
in the elderly (1–2). However, there have
been few reports investigating the associ-
ation of SO with metabolic syndrome,
particularly in Asian ethnic groups. The
aimofthepresentstudywastoinvestigate
the prevalence of SO and its association
with metabolic syndrome in a communi-
ty-based elderly cohort in Korea.
RESEARCH DESIGN AND
METHODS— Thisstudywasapartof
the Korean Longitudinal Study on Health
andAging(KLoSHA),whichhasbeende-
scribed in detail (3). Appendicular skele-
tal muscle mass (ASM) was measured by
dual energy X-ray absorptiometry (DXA;
Lunar Corporation, Madison, WI). We
used two deﬁnitions for sarcopenia: 1)
ASM divided by height squared (ASM/
Ht
2) (kg/m
2), as proposed by Baumgart-
neretal.(4)and2)ASMasapercentageof
body weight (ASM/Wt), which was mod-
iﬁed from the study of Janssen et al. (5).
Sarcopenia was deﬁned as 1 SD below
the sex-speciﬁc mean for a young refer-
ence group. The cutoff point for sarcope-
nia was 7.09 kg/m
2 in men and 5.27
kg/m
2inwomenasmeasuredusingASM/
Ht
2.ForASM/Wt,thecutoffwas29.9%in
men and 25.1% in women. The sex-
speciﬁc young reference group included
32menand38women.Theirmeanage
SD was 28.4  3.1 and 26.3  2.6 years,
respectively. Obesity was deﬁned as a
visceralfatareaexceeding100cm
2onab-
dominal computed tomography (Soma-
tom Sensation 16; Siemens, Munich,
Germany) (6). The subjects were classi-
ﬁed into sarcopenic obese, obese, sar-
copenic, and normal groups according to
the deﬁnitions set out above.
Metabolic syndrome was deﬁned ac-
cording to the National Cholesterol Edu-
cation Program criteria using the Asia-
Paciﬁc abdominal obesity criteria (waist
circumference 90 cm in men and 80
cm in women) (7–8). Differences be-
tween the four groups were tested using
ANOVA. Pearson’s correlation and multi-
ple logistic regression models were used.
P  0.05 was considered statistically
signiﬁcant.
RESULTS— TheprevalenceofSOwas
16.7% in men and 5.7% in women with
sarcopenia deﬁned by ASM/Ht
2. How-
ever, it was 35.1% in men and 48.1% in
women when deﬁned by ASM/Wt. When
sarcopenia was deﬁned by ASM/Ht
2, the
obesegroupshowedahigherBMI,greater
waist circumference, more visceral fat
mass, and more insulin resistance than
any other group in either sex, although
theSOgrouphadpoorerproﬁlesthanthe
group with sarcopenia alone. In contrast,
theSOgroupdeﬁnedbyASM/Wtshowed
a higher BMI, more visceral fat mass, and
more insulin resistance than any other
group in either sex (Table 1).
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eride level in the men of the SO group
deﬁned by ASM/Wt was signiﬁcantly
higher than that of other groups. Fasting
glucose concentration of the SO group
seems to be higher than that of other
groups although it was not statistically
signiﬁcant.
We calculated the odds ratios from
logisticregressionmodelspredictingmet-
abolic syndrome controlled for age, sex,
smoking status, alcohol consumption,
andexercisehabits.Inthecaseofsarcope-
niadeﬁnedbyASM/Wt,theSOgrouphad
an 8.2 times (95% CI 4.45–15.40) and
the obese group had a 5.5 times (2.81–
10.80)higherriskofmetabolicsyndrome
than the normal group. In contrast, using
ASM/Ht
2, the odds ratio for metabolic
syndrome was 2.90 (1.28–6.57) in the
obese group and 4.80 (2.63–8.75) in the
SO group.
CONCLUSIONS — We found that
the SO group deﬁned by ASM/Wt had a
higherriskofhavingmetabolicsyndrome
than the obese or sarcopenic groups. In-
tuitively, having a high fat mass with low
muscle mass seems likely to lead to more
functional limitations and metabolic dis-
orders. Adipocytes actively secrete leptin
and proinﬂammatory cytokines, which
stimulate muscle catabolism. These fac-
tors activate a vicious cycle leading to ac-
celerated sarcopenia, additional weight
gain largely in the form of fat, and ulti-
mately to physical disability (1,9–12).
Therefore, it is appropriate to consider
obesitytogetherwithsarcopeniaintheel-
derly population.
However,therehasbeensomedebate
as to whether SO leads to metabolic syn-
drome. Baumgartner et al. (1) showed
that the prevalence of metabolic syn-
drome was highest in the group of non-
sarcopenic obese subjects. In contrast,
Stephen and Janssen (13) reported that
SO was associated with a 23% increased
risk of cardiovascular disease in a large
sample of community-dwelling elderly
adults during 10 years of follow-up.
These discrepancies might have arisen
from different deﬁnitions of SO and dif-
ferent subjects.
When ASM/Wt was used as a deﬁner,
the SO group was more insulin resistant
and at a higher risk for metabolic syn-
drome than the obese or sarcopenic
groups in both sexes. Furthermore, ASM/
Ht
2waspositivelycorrelatedwithBMI,vis-
ceral fat area, and the homeostasis model
assessment of insulin resistance measure in
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atively correlated with these factors.
Therefore, we suggest that ASM/Wt is
the more appropriate index for SO.
This study had several advantages
overpreviousstudies.First,subjectswere
recruited from a community-based el-
derly population, represented a single
ethnic group, and were all aged 65 years
or older. Second, previous studies used
BMI or the percentage of fat mass for the
deﬁnition of obesity to obtain a sufﬁcient
number of subjects within the group for
statistical analysis (14). In contrast, we
used the criterion of visceral fat area for
deﬁning abdominal obesity, which is
known to be highly associated with met-
abolic impairment (6). In this study, peo-
ple with a visceral fat area  100 cm
2
showed relatively low BMI or waist cir-
cumference compared with Caucasians.
There were several limitations of this
study. First, the cross-sectional nature of
thisstudymakesitimpossibletointerpret
any cause-effect relationship. Second, we
did not consider muscle quality or the in-
ﬁltration of fat into muscle, which has
beenshowntobeassociatedwithreduced
strength, the incidence of mobility dis-
ability, and insulin resistance (13,15).
In conclusion, subjects with SO de-
ﬁnedbyASM/Wtweremoreinsulinresis-
tant and had a higher risk for metabolic
syndrome than simply obese or sar-
copenic subjects.
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